Title: CorrespondenceUpdosing of secukinumab to every 2 weeks results in superior efficacy in patients with severe psoriasis weighing 90 kg or more: a real-world prospective observational study.
Authors: McGuire, Niamh; Elamin, Shahd; Gough, Pamela; Cooke, Nicola; McGrath, Conor; McKenna, Kevin; O'Kane, Donal
Abstract: At baseline assessment, patients on monthly dosing had a mean reduction in PASI and DLQI of 12.7 and 4.3, respectively, with two patients achieving PASI 75 and zero achieving PASI 90. Dear Editor, Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A in the treatment of moderate-to-severe plaque psoriasis.
Subjects: PSORIASIS; LONGITUDINAL method; SCIENTIFIC observation
Publication: Clinical & Experimental Dermatology, 2023, Vol 48, Issue 7, p793
ISSN: 0307-6938
Publication type: Academic Journal
DOI: 10.1093/ced/llad035

CorrespondenceUpdosing of secukinumab to every 2 weeks results in superior efficacy in patients with severe psoriasis weighing 90 kg or more: a real-world prospective observational study.

McGuire, Niamh; Elamin, Shahd; Gough, Pamela; Cooke, Nicola; McGrath, Conor; McKenna, Kevin; O'Kane, Donal